Related Experiment Video

Updated: Mar 2, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

19.9K

High or low birth weight may increase risk of liver disease

    Nursing Standard (Royal College of Nursing (Great Britain) : 1987)
    |May 11, 2017
    PubMed

    Insights

    Children with high or low birth weight face higher risks for non-alcoholic fatty liver disease (NAFLD). This finding highlights the importance of monitoring liver health in relation to birth weight.

    Area of Science:

    • Pediatrics
    • Hepatology
    • Public Health

    Background:

    • Non-alcoholic fatty liver disease (NAFLD) is a growing global health concern.
    • Birth weight is a critical indicator of early life development and potential long-term health outcomes.
    • Existing research suggests various factors influencing NAFLD development, but the specific role of birth weight extremes requires further investigation.

    Purpose of the Study:

    • To investigate the association between high or low birth weight and the risk of developing non-alcoholic fatty liver disease in children.
    • To identify potential early life predictors for NAFLD.
    • To inform public health strategies for NAFLD prevention.

    Main Methods:

    • Retrospective cohort study design.
    • Analysis of a large dataset of pediatric patients.
    • Statistical modeling to assess the correlation between birth weight categories (e.g., low birth weight, high birth weight) and NAFLD diagnosis.

    Main Results:

    • Children born with low birth weight demonstrated an elevated risk of developing NAFLD.
    • Conversely, children with high birth weight also exhibited an increased susceptibility to NAFLD.
    • A significant association was found between both extremes of birth weight and subsequent NAFLD diagnosis.

    Conclusions:

    • Both low and high birth weight are identified as significant risk factors for the development of non-alcoholic fatty liver disease in children.
    • Birth weight serves as a potential early screening marker for identifying children at risk of NAFLD.
    • Further research is warranted to explore the underlying mechanisms and clinical implications of this association.

    More Related Videos

    Vinyl Chloride and High-Fat Diet as a Model of Environment and Obesity Interaction09:15

    Vinyl Chloride and High-Fat Diet as a Model of Environment and Obesity Interaction

    Published on: January 12, 2020

    6.9K
    Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish09:27

    Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

    Published on: April 1, 2021

    4.0K

    Related Concept Videos

    Diseases of the Liver and Gallbladder01:26

    Diseases of the Liver and Gallbladder

    Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
    Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
    2.2K
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
    244
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
    302
    Overview of Lipid Metabolism01:24

    Overview of Lipid Metabolism

    Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
    Lipolysis: The Breakdown of Lipids:
    Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
    6.1K
    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

    Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
    317
    Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

    Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

    Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
    250